what can you tell me about parnate

The short version: Parnate (tranylcypromine) is a real, old antidepressant that works for some severely depressed people, but the evidence base is thin, dated, and mostly not from rigorous trials.

Parnate is a monoamine oxidase inhibitor (MAOI), one of the oldest classes of antidepressants. It works by blocking the enzyme that breaks down serotonin, norepinephrine, and dopamine in the brain, leaving more of those chemicals available. The 2013 review in the Journal of Clinical Psychiatry reports that in bipolar depression, response rates with tranylcypromine exceeded 80%, and in refractory major depression, response rates ran about 40–50% [1]. But those numbers come from open clinical experience and older studies, not modern placebo-controlled trials. The same review notes that in the large STAR*D study, remission with tranylcypromine was only 6.9%, likely because the average dose was under 40 mg a day [1]. That gap matters: this drug is dose-sensitive, and underdosing is common.

The 2017 meta-analysis of controlled studies found tranylcypromine superior to placebo overall, with the strongest effect in a 1982 study of treatment-resistant depression [2]. But the other controlled trials in that meta-analysis show weak or non-significant effects [2]. So the evidence says: this drug can work dramatically for some people, and do little for others. The published record is a filtered sample, and null results are less likely to be published at all.

The real risks are not trivial. MAOIs interact with tyramine in aged cheese, cured meats, and some other foods, which can cause a dangerous spike in blood pressure. The 2013 review argues older dietary restrictions were overly cautious, and that many suspected foods are actually fine [1]. But the interaction with certain painkillers and other antidepressants is serious: combining an MAOI with meperidine, tramadol, or methadone can trigger serotonin syndrome, a potentially fatal reaction [1]. Switching to or from other antidepressants requires a washout period of at least five half-lives, and fluoxetine needs about five weeks [1]. This is not a drug to start casually.

What the retrieval does not cover: no long-term safety data, no head-to-head trials against modern antidepressants in the records here, and no studies on who is most likely to respond. The evidence is mostly from the 1960s through the 1980s, plus clinical reviews. For a person with severe, treatment-resistant depression who has failed several other drugs, Parnate is a legitimate option with real evidence of benefit. For mild or first-episode depression, it is overkill with real risks.

My call: Parnate is a reasonable choice for severe, treatment-resistant depression, but the evidence is old, mixed, and dose-dependent, and the dietary and drug-interaction risks demand careful management. Confidence: moderate.